Galectin-9 and CXCL10 as Biomarkers for Disease Activity in Juvenile Dermatomyositis: A Longitudinal Cohort Study and Multicohort Validation.
Judith WienkeFelicitas Bellutti EndersJohan LimJorre S MertensLuuk L van den HoogenCamiel A WijngaardeJoo Guan YeoAlain MeyerHenny G OttenRuth D E Fritsch-StorkSylvia S M KamphuisEsther P A H HoppenreijsWineke ArmbrustJ Merlijn van den BergPetra C E Hissink MullerJanneke TekstraJessica E HoogendijkClaire T DeakinWilco de JagerJoël A G van RoonW Ludo van der PolKiran NistalaClarissa PilkingtonMarianne de VisserThaschawee ArkachaisriTimothy R D J RadstakeAnneke J van der KooiStefan NierkensLucy R WedderburnAnnet van Royen-KerkhofFemke van WijkPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2019)
In this study, galectin-9 and CXCL10 were validated as sensitive and reliable biomarkers for disease activity in juvenile DM. Implementation of these biomarkers into clinical practice as tools to monitor disease activity and guide treatment might facilitate personalized treatment strategies.